{"id":45463,"date":"2026-04-07T18:46:25","date_gmt":"2026-04-07T18:46:25","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/45463\/"},"modified":"2026-04-07T18:46:25","modified_gmt":"2026-04-07T18:46:25","slug":"novartis-uses-us-bond-issue-to-expand-rna-and-peptide-pipeline","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/45463\/","title":{"rendered":"Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline"},"content":{"rendered":"\n

Find winning stocks<\/a> in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.<\/p>\n

Novartis (SWX:NOVN) issues US$11b in US dollar bonds to fund its planned US$12b acquisition of Avidity Biosciences.<\/p>\n

The bond financing highlights the company\u2019s focus on expanding its medicines portfolio through large-scale M&A.<\/p>\n

Separately, Novartis signs a licensing agreement with Unnatural Products for macrocyclic peptide therapeutics targeting cardiovascular disease.<\/p>\n

Both moves add new platforms and modalities to the Novartis pipeline beyond recent product approvals and corporate governance updates.<\/p>\n

Novartis is a global medicines group with a focus on prescription drugs, where competition for differentiated pipelines and drug discovery platforms remains intense. Large pharmaceutical companies continue to use M&A and licensing to access new technologies and treatment areas, particularly where internal R&D may not cover every target class. In this context, the Avidity Biosciences deal and the Unnatural Products agreement place SWX:NOVN in the middle of two active areas: RNA based therapies and complex peptide drugs.<\/p>\n

For investors, these moves matter less for near term earnings and more for how they shape the mix of future product candidates and partnership economics. The combination of bond financing, acquisition activity and external collaborations provides additional angles to monitor when assessing risk, balance sheet flexibility and the potential breadth of the Novartis pipeline over the coming years.<\/p>\n

Stay updated on the most important news stories for Novartis<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novartis.<\/p>\n

\"SWX:NOVN<\/a> SWX:NOVN Earnings & Revenue Growth as at Mar 2026 <\/p>\n

\ud83d\udcf0 Beyond the headline: 1 risk and 5 things going right for Novartis that every investor should see.<\/a><\/p>\n

\u2696\ufe0f Price vs Analyst Target: At CHF119.50 against a consensus target of about CHF120.11, the share price is roughly in line with analyst expectations.<\/p>\n

\u2705 Simply Wall St Valuation: Shares are described as trading about 58.9% below an estimated fair value, which flags a large valuation gap.<\/p>\n

\u274c Recent Momentum: The 30 day return of about 5.5% decline shows weak short term price momentum.<\/p>\n

There is only one way to know the right time to buy, sell or hold Novartis. Head to the Simply Wall St company report for the latest analysis of Novartis’s Fair Value..<\/p>\n

\ud83d\udcca The Avidity acquisition and Unnatural Products licensing deal expand Novartis’ reach into RNA and peptide therapies, which could influence long term earnings mix if programs advance.<\/p>\n

\ud83d\udcca Keep an eye on how the CHF119.50 price compares with the P\/E of about 20.6 versus the Pharmaceuticals industry average and on any updates to the estimated fair value gap.<\/p>\n

\u26a0\ufe0f The bond funded US$11b deal comes alongside an existing flag for a high level of debt, so investors may want to track leverage, interest costs and credit metrics over time.<\/p>\n

For the full picture including more risks and rewards, check out the complete Novartis analysis. Alternatively, you can check out the community page for Novartis<\/a> to see how other investors believe this latest news will impact the company’s narrative.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVN.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…\n","protected":false},"author":2,"featured_media":18088,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[7849,8786,206,9367,8774],"class_list":{"0":"post-45463","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-avidity-biosciences","9":"tag-licensing-agreement","10":"tag-novartis","11":"tag-peptide-therapeutics","12":"tag-unnatural-products"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116364914605846687","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/45463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=45463"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/45463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18088"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=45463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=45463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=45463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}